Clinical Trials Browser

Phase 2/3 × futibatinib × 30 days × Clear all

NCT06506955 2026-05-28

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma